NCT05067868 - A Study of Replagal in Children and Adults With Fabry Disease in India | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

October 31, 2026

Study Completion Date

November 30, 2026

Conditions

Fabry Disease

Interventions

BIOLOGICAL

Replagal

Participants will receive Replagal 0.2 mg/kg, intravenous infusion at Day 1 and every 2 weeks.

Trial Locations (3)

RECRUITING

All India Institute of Medical Sciences (AIIMS), New Delhi

RECRUITING

Sir Gangaram Hospital, New Delhi

NOT_YET_RECRUITING

Institute of Child Health, Kolkata